Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments
Malignant pleural mesothelioma (MPM) is an aggressive cancer, associated with poor prognosis. We assessed the feasibility of patient-derived cell cultures to serve as an ex vivo model of MPM. Patient-derived MPM cell cultures (n=16) exhibited stemness features and reflected intratumour and interpati...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020
|
| _version_ | 1797054879534940160 |
|---|---|
| author | Kanellakis, NI Asciak, R Hamid, MA Yao, X McCole, M McGowan, S Seraia, E Hatch, S Hallifax, RJ Mercer, RM Bedawi, EO Jones, S Verrill, C Dobson, M George, V Stathopoulos, GT Peng, Y Ebner, D Dong, T Rahman, NM Psallidas, I |
| author_facet | Kanellakis, NI Asciak, R Hamid, MA Yao, X McCole, M McGowan, S Seraia, E Hatch, S Hallifax, RJ Mercer, RM Bedawi, EO Jones, S Verrill, C Dobson, M George, V Stathopoulos, GT Peng, Y Ebner, D Dong, T Rahman, NM Psallidas, I |
| author_sort | Kanellakis, NI |
| collection | OXFORD |
| description | Malignant pleural mesothelioma (MPM) is an aggressive cancer, associated with poor prognosis. We assessed the feasibility of patient-derived cell cultures to serve as an ex vivo model of MPM. Patient-derived MPM cell cultures (n=16) exhibited stemness features and reflected intratumour and interpatient heterogeneity. A subset of the cells were subjected to high-throughput drug screening and coculture assays with cancer-specific cytotoxic T cells and showed diverse responses. Some of the biphasic MPM cells were capable of processing and presenting the neoantigen SSX-2 endogenously. In conclusion, patient-derived MPM cell cultures are a promising and faithful ex vivo model of MPM. |
| first_indexed | 2024-03-06T19:03:28Z |
| format | Journal article |
| id | oxford-uuid:1456316f-e482-4bbc-8db5-98648b0caa69 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:03:28Z |
| publishDate | 2020 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:1456316f-e482-4bbc-8db5-98648b0caa692022-03-26T10:19:24ZPatient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatmentsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1456316f-e482-4bbc-8db5-98648b0caa69EnglishSymplectic ElementsBMJ Publishing Group2020Kanellakis, NIAsciak, RHamid, MAYao, XMcCole, MMcGowan, SSeraia, EHatch, SHallifax, RJMercer, RMBedawi, EOJones, SVerrill, CDobson, MGeorge, VStathopoulos, GTPeng, YEbner, DDong, TRahman, NMPsallidas, IMalignant pleural mesothelioma (MPM) is an aggressive cancer, associated with poor prognosis. We assessed the feasibility of patient-derived cell cultures to serve as an ex vivo model of MPM. Patient-derived MPM cell cultures (n=16) exhibited stemness features and reflected intratumour and interpatient heterogeneity. A subset of the cells were subjected to high-throughput drug screening and coculture assays with cancer-specific cytotoxic T cells and showed diverse responses. Some of the biphasic MPM cells were capable of processing and presenting the neoantigen SSX-2 endogenously. In conclusion, patient-derived MPM cell cultures are a promising and faithful ex vivo model of MPM. |
| spellingShingle | Kanellakis, NI Asciak, R Hamid, MA Yao, X McCole, M McGowan, S Seraia, E Hatch, S Hallifax, RJ Mercer, RM Bedawi, EO Jones, S Verrill, C Dobson, M George, V Stathopoulos, GT Peng, Y Ebner, D Dong, T Rahman, NM Psallidas, I Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments |
| title | Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments |
| title_full | Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments |
| title_fullStr | Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments |
| title_full_unstemmed | Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments |
| title_short | Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments |
| title_sort | patient derived malignant pleural mesothelioma cell cultures a tool to advance biomarker driven treatments |
| work_keys_str_mv | AT kanellakisni patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT asciakr patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT hamidma patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT yaox patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT mccolem patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT mcgowans patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT seraiae patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT hatchs patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT hallifaxrj patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT mercerrm patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT bedawieo patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT joness patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT verrillc patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT dobsonm patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT georgev patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT stathopoulosgt patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT pengy patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT ebnerd patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT dongt patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT rahmannm patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments AT psallidasi patientderivedmalignantpleuralmesotheliomacellculturesatooltoadvancebiomarkerdriventreatments |